CareDx, Inc
CDNA · Price history
Price at last available close
$72.13
+$8.11 (+12.67%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About CareDx, Inc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients.
How they make money
CareDx generates revenue primarily through the sale of non-invasive molecular testing services and digital health solutions for transplant patients. The company operates a commercial model focused on transplant centers, relying on obtaining and maintaining reimbursement coverage from third-party payers, including Medicare and private insurance, for its diagnostic offerings.
Products & services
Integrated solutions including non-invasive molecular testing for heart, kidney, and lung transplants, laboratory products, digital health technologies, and patient support services.
Brands & revenue mix
Diagnostic solution for cell therapy and hematologic malignancies.
Separate brand revenue is not available in this research.Source
Multiomics discovery platform.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Customer concentration
The company discloses that a significant portion of its revenue is derived from Medicare, which accounted for approximately 37% of total revenue for the three months ended March 31, 2025.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Business relationships & partnerships
- 10x Genomics — Strategic collaboration to launch ImmuneScape, a multiomics discovery platform for transplant diagnostics.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
40
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
66
Fair
Financial Strength
72
Business Quality / Moat
75
Management
80
Growth Quality
56
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
31
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CDNA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CDNA maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is CDNA's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is CDNA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What future growth or profitability would be needed to justify CDNA's current valuation?
Essential Investment Snapshot
Wall Street Score
40
Opportunity Score
31
Market Cap
$3.73B
P/E Ratio
30.2
EPS
$2.15
52-Week High
$65.63
52-Week Low
$13.95
Beta
2.43
Intrinsic Value
$42.74
Analyst Target
$64.50
Shares Outstanding
53.3M
Total Revenue
$458.1M
Total Debt
$19.2M
Dividend
No current dividend
Liquidation Value / Share
$7.99
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CDNA
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on CDNA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Innovated go-to-market model for lab developed tests.
- +Integrated portfolio of solutions for transplant centers.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Billing and reimbursement complexities.
- −Legal proceedings and litigation.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
41
Sep 14, 2026
Change
-1.1
points
Current Score
40
Oct 1, 2026
Category Changes
CDNA decreased 1.1 points because Capital declined by 4 points, Valuation declined by 5.9 points.
Negative Contributors
- − Capital declined by 4 points
- − Valuation declined by 5.9 points
Projected Score
Projected Score
46
Projected Change
+6.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 6.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$72.13
Model Intrinsic Value
$42.74
Difference
+$29.39
+68.8% vs IV
Margin of Safety
-68.8%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $458.1M | $379.8M | $333.8M | $280.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $134.8M | $123.2M | $109.6M | $102.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $323.3M | $256.6M | $224.2M | $178.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $79.9M | $71.4M | $72.4M | $81.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $247.7M | $210.2M | $205.5M | $201.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $327.6M | $281.6M | $183.4M | $381.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $15.6M | -$4.7M | -$34.0M | -$84.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$4.2M | -$25.1M | $40.8M | -$203.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $115.2M | -$21.1M | $52.9M | -$190.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $4.2M | $271K | $310K | $141K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $111.0M | -$21.4M | $52.5M | -$190.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $2.15 | $-0.40 | $1.00 | $-3.54 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 51.47M | 53.29M | 52.77M | 53.76M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 53.42M | 53.29M | 56.62M | 53.76M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$131.9M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$2.07
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-33.9%
Cash Change
+447.8%
Margin Change
+93.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 52.2%. EPS declined 1393.7%. Cash increased 447.8%. Total debt declined 33.9%. Net income margin improved by 93.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx Inc (CDNA) Shares Fall 4.0% -- GF Value Says Still Overvalued
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
Rumor Mill · CDNA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial